Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 12/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 9/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.49 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.49 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.49 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.49 |
| ▸ | RPS27 | P42677 | 4/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1145009 | 0.85 | MAPK8 (0.60) | MAPK8MAPK9PRKD3MAPK10MAP4K4 | |
| SCHEMBL9820174 | 0.83 | ALDH1A1 (0.57) | RECQLKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL17163957 | 0.81 | RECQL (0.67) | MAPK8MAPK9RECQLKDM4ESQOR | |
| SCHEMBL20606873 | 0.77 | MAPK8 (0.59) | MAPK8MAPK9PRKD3MAPK10MAP4K4 | |
| SCHEMBL553686 | 0.73 | KDM4E (0.55) | RECQLKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30411552 | 0.73 | KDM4E (0.71) | RECQLKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1140140 | 0.73 | KDM4E (0.71) | RECQLKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30370553 | 0.73 | KDM4E (0.55) | RECQLKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1145693 | 0.73 | MAPK8 (0.61) | MAPK8MAPK9PRKD3MAPK10MAP4K4 | |
| SCHEMBL1145762 | 0.72 | MAPK8 (0.63) | MAPK8MAPK9PRKD3MAPK10MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | MAPK8 3418/4885MAPK9 3203/4885PRKD3 30/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | MAPK8 3418/4885MAPK9 3203/4885PRKD3 30/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | MAPK8 3418/4885MAPK9 3203/4885PRKD3 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.